Appropriate sequence for afatinib and cisplatin combination improves anticancer activity in head and neck squamous cell carcinoma

Research output: Contribution to journalArticle

7 Downloads (Pure)

Abstract

Despite a better understanding in head and neck tumors pathogenesis as well as improvements in radiotherapy and surgery, locally advanced head and neck squamous cell carcinoma (HNSCC) remains of poor prognosis. One promising target is the epidermal growth factor receptor (EGFR), which is overexpressed in the majority of HNSCC and is associated to tumor progression and resistance to treatment. However, in several clinical trials, the combination of EGFR inhibitors with chemotherapy and/or radiotherapy generates moderate results. In this study, we investigated the anti-tumor activity of afatinib, an irreversible pan-EGFR inhibitor, combined to cisplatin in different schedules of exposure. For that, we used two human EGFR wild-type HNSCC cell lines and we evaluated the cytotoxicity of the two drugs combined in different sequences. The efficiency of each strategy was assessed by evaluating the effects on cell cycle distribution, DNA damage, cell death and downstream pathways of ErbB family receptors. We demonstrated that cisplatin treatment followed by afatinib exposure displayed more cytotoxic effects than the opposite timing or than simultaneous association. This higher anticancer activity is probably due to afatinibinduced cell cycle arrest, which prevents the repair of cisplatin-induced DNA damage and promotes cell death by various mechanisms including apoptosis. These data suggest the importance of an appropriate timing administration between an EGFR inhibitor and a conventional chemotherapy in order to obtain the best clinical benefit for patients with a head and neck cancer.

Original languageEnglish
Article number432
Pages (from-to)432
Number of pages10
JournalFrontiers in Oncology
Volume8
Issue numberOCT
DOIs
Publication statusPublished - 2018

Fingerprint

Epidermal Growth Factor Receptor
Cisplatin
DNA Damage
Cell Death
Radiotherapy
Drug Therapy
Neoplasms
Head and Neck Neoplasms
Cell Cycle Checkpoints
Appointments and Schedules
Cell Cycle
Neck
Head
BIBW 2992
Carcinoma, squamous cell of head and neck
Clinical Trials
Apoptosis
Cell Line
Therapeutics
Pharmaceutical Preparations

Keywords

  • Afatinib
  • Cisplatin
  • Combined therapy
  • Head and neck squamous cell carcinoma
  • Treatment schedule

Cite this

@article{59f0381d392b499a8cdf194f232af597,
title = "Appropriate sequence for afatinib and cisplatin combination improves anticancer activity in head and neck squamous cell carcinoma",
abstract = "Despite a better understanding in head and neck tumors pathogenesis as well as improvements in radiotherapy and surgery, locally advanced head and neck squamous cell carcinoma (HNSCC) remains of poor prognosis. One promising target is the epidermal growth factor receptor (EGFR), which is overexpressed in the majority of HNSCC and is associated to tumor progression and resistance to treatment. However, in several clinical trials, the combination of EGFR inhibitors with chemotherapy and/or radiotherapy generates moderate results. In this study, we investigated the anti-tumor activity of afatinib, an irreversible pan-EGFR inhibitor, combined to cisplatin in different schedules of exposure. For that, we used two human EGFR wild-type HNSCC cell lines and we evaluated the cytotoxicity of the two drugs combined in different sequences. The efficiency of each strategy was assessed by evaluating the effects on cell cycle distribution, DNA damage, cell death and downstream pathways of ErbB family receptors. We demonstrated that cisplatin treatment followed by afatinib exposure displayed more cytotoxic effects than the opposite timing or than simultaneous association. This higher anticancer activity is probably due to afatinibinduced cell cycle arrest, which prevents the repair of cisplatin-induced DNA damage and promotes cell death by various mechanisms including apoptosis. These data suggest the importance of an appropriate timing administration between an EGFR inhibitor and a conventional chemotherapy in order to obtain the best clinical benefit for patients with a head and neck cancer.",
keywords = "Afatinib, Cisplatin, Combined therapy, Head and neck squamous cell carcinoma, Treatment schedule",
author = "Eleonore Longton and Kathleen Schmit and Maude Fransolet and Fran{\cc}ois Clement and Carine Michiels",
year = "2018",
doi = "10.3389/fonc.2018.00432",
language = "English",
volume = "8",
pages = "432",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Research Foundation",
number = "OCT",

}

TY - JOUR

T1 - Appropriate sequence for afatinib and cisplatin combination improves anticancer activity in head and neck squamous cell carcinoma

AU - Longton, Eleonore

AU - Schmit, Kathleen

AU - Fransolet, Maude

AU - Clement, François

AU - Michiels, Carine

PY - 2018

Y1 - 2018

N2 - Despite a better understanding in head and neck tumors pathogenesis as well as improvements in radiotherapy and surgery, locally advanced head and neck squamous cell carcinoma (HNSCC) remains of poor prognosis. One promising target is the epidermal growth factor receptor (EGFR), which is overexpressed in the majority of HNSCC and is associated to tumor progression and resistance to treatment. However, in several clinical trials, the combination of EGFR inhibitors with chemotherapy and/or radiotherapy generates moderate results. In this study, we investigated the anti-tumor activity of afatinib, an irreversible pan-EGFR inhibitor, combined to cisplatin in different schedules of exposure. For that, we used two human EGFR wild-type HNSCC cell lines and we evaluated the cytotoxicity of the two drugs combined in different sequences. The efficiency of each strategy was assessed by evaluating the effects on cell cycle distribution, DNA damage, cell death and downstream pathways of ErbB family receptors. We demonstrated that cisplatin treatment followed by afatinib exposure displayed more cytotoxic effects than the opposite timing or than simultaneous association. This higher anticancer activity is probably due to afatinibinduced cell cycle arrest, which prevents the repair of cisplatin-induced DNA damage and promotes cell death by various mechanisms including apoptosis. These data suggest the importance of an appropriate timing administration between an EGFR inhibitor and a conventional chemotherapy in order to obtain the best clinical benefit for patients with a head and neck cancer.

AB - Despite a better understanding in head and neck tumors pathogenesis as well as improvements in radiotherapy and surgery, locally advanced head and neck squamous cell carcinoma (HNSCC) remains of poor prognosis. One promising target is the epidermal growth factor receptor (EGFR), which is overexpressed in the majority of HNSCC and is associated to tumor progression and resistance to treatment. However, in several clinical trials, the combination of EGFR inhibitors with chemotherapy and/or radiotherapy generates moderate results. In this study, we investigated the anti-tumor activity of afatinib, an irreversible pan-EGFR inhibitor, combined to cisplatin in different schedules of exposure. For that, we used two human EGFR wild-type HNSCC cell lines and we evaluated the cytotoxicity of the two drugs combined in different sequences. The efficiency of each strategy was assessed by evaluating the effects on cell cycle distribution, DNA damage, cell death and downstream pathways of ErbB family receptors. We demonstrated that cisplatin treatment followed by afatinib exposure displayed more cytotoxic effects than the opposite timing or than simultaneous association. This higher anticancer activity is probably due to afatinibinduced cell cycle arrest, which prevents the repair of cisplatin-induced DNA damage and promotes cell death by various mechanisms including apoptosis. These data suggest the importance of an appropriate timing administration between an EGFR inhibitor and a conventional chemotherapy in order to obtain the best clinical benefit for patients with a head and neck cancer.

KW - Afatinib

KW - Cisplatin

KW - Combined therapy

KW - Head and neck squamous cell carcinoma

KW - Treatment schedule

UR - http://www.scopus.com/inward/record.url?scp=85055342665&partnerID=8YFLogxK

UR - https://www.frontiersin.org/article/10.3389/fonc.2018.00432/full

UR - http://www.mendeley.com/research/appropriate-sequence-afatinib-cisplatin-combination-improves-anticancer-activity-head-neck-squamous

U2 - 10.3389/fonc.2018.00432

DO - 10.3389/fonc.2018.00432

M3 - Article

AN - SCOPUS:85055342665

VL - 8

SP - 432

JO - Frontiers in Oncology

JF - Frontiers in Oncology

SN - 2234-943X

IS - OCT

M1 - 432

ER -